medigraphic.com

2020, Number 3

<< Back Next >>

Rev Cuba Endoc 2020; 31 (3)

Use of the hypertension-abdominal obesity phenotype to identify people with moderate and high overall cardiovascular risk

Parlá SJ, Cabrera RE, Rodríguez AJ, Cubas DI, Arnold DY, Hernández RJ, Díaz-Díaz O

Language: Spanish
References: 54
Page: 1-13
PDF size: 333.07 Kb.


ABSTRACT

Introduction: Obesity is linked to a high risk of non-communicable diseases. A growing trend in the prevalence of obesity since the early 1980s has posed a significant population´s health burden worldwide.
Objectives: Determine the usefulness of the hypertension- abdominal obesity´s phenotype to identify cases with moderate or high overall cardiovascular risk in adults with excess body weight and whether it is superior to that of other phenotypic binomials described and to the metabolic syndrome.
Methods: Observational, descriptive and cross-sectional study that included 257 people from 35 to 70 years old. Variables studied: age, sex, weight, size, body mass index, waist circumference, blood pressure, cholesterol, triglycerides, HDL cholesterol and fasting blood glucose. The presence of metabolic syndrome was determined according to the criteria of the Joint Interim Statement (JIS), and hypertension- abdominal obesity phenotypes, abdominal hypertriglyceridemia-obesity and hyperglycemia- abdominal obesity were also studied. The overall cardiovascular risk was assessed using Gaziano's tables.
Results: 81.7% (210/257) of subjects had the hypertension-abdominal obesity´s phenotype and the frequency of moderate-high cardiovascular risk was 28.0% (72/257).The hypertension- abdominal obesity´s phenotype detected the highest proportion of subjects at moderate-high cardiovascular risk (64 of the 72); moderate-high cardiovascular risk was present in most of the subjects with this phenotype (88.8%), different from those without the phenotype (11.1%).Sensitivity (88.9%) and the negative predictive value (83.0%) show that the hypertension- abdominal obesity´s phenotype is a useful binomial for detecting individuals with moderate-high cardiovascular risk.
Conclusions: The usefulness of the hypertension- abdominal obesity phenotype is superior to that of other phenotypic binomials and to the metabolic syndrome in order to identify people with moderate-high cardiovascular risk. The high sensitivity and high negative predictive value of the hypertension- abdominal obesity phenotype, as well as the simplicity of its determination, make it a good option for researching subjects with this risk.


REFERENCES

  1. World Health Organization. Obesity and overweight. 2020[acceso: 21/08/2020]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

  2. Global Burden of Disease Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017,377(1):13-27.

  3. Inoue Y, Qin B, Poti J, Sokol R, Gordon-Larsen P. Epidemiology of obesity in adults: latest trends. Curr Obes Rep. 2018;7(4):276-88.

  4. OMS. Obesidad y sobrepeso. 2020[acceso: 21/08/2020]. Disponible en: http://www.who.int/mediacentre/factsheets/fs311/es/

  5. Bonet M, Varona P, Chang M, García RG, Suarez R, Arcía N, et al. III Encuesta nacional de factores de riesgo y actividades preventivas de enfermedades no trasmisibles. Cuba 2010-2011. La Habana: Editorial Ciencias Médicas; 2015. pp. 110-37.

  6. Instituto Nacional de Higiene, Epidemiología y Microbiología. II Encuesta Nacional de Factores de Riesgo y Enfermedades No Transmisibles. Principales resultados por provincias. La Habana: INHEM; 2002.

  7. Colectivo de autores. II Consenso Latinoamericano de Obesidad 2017. Federación Latinoamericana de Sociedades de Obesidad. 2017[acceso: 30/05/2017]:144. Disponible en: http://fliphtml5.com/hvov/cxpr/basic

  8. Hernández Rodríguez J, Arnold Domínguez Y, Moncada Espinal OM. Prevalencia y tendencia actual del sobrepeso y la obesidad en personas adultas en el mundo. Rev Cubana de Endocrinol. 2019[acceso: 02/09/2019];30(3):e193. Disponible en: http://www.revendocrinologia.sld.cu/index.php/endocrinologia/article/view/193/167

  9. Millán Núñez-Cortes J, Mantilla Morato T, Toro R, Millán Pérez J, Mangas Rojas A. Síndrome metabólico en pacientes con fenotipo clínico de "cintura hipertrigliceridémica. Nutr Hosp. 2015;32(3):1145-52.

  10. Fernández JC. Síndrome metabólico y riesgo cardiovascular. Rev CENIC Ciencias Biológicas. 2016;47(2):106-19.

  11. Lam DW, LeRoith D. Metabolic Syndrome. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; February 11, 2019[acceso: 21/08/2020]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25905173/

  12. Reaven G. Insulin resistance and coronary heart disease in nondiabetic individuals. Arterioscler Thromb Vasc Biol. 2012;32(8):1754-9.

  13. Bergman, M, Chetrit A, Roth J, Danker R. Dysglycemia and long-term mortality: Observations from the Israel study of glucose intolerance, obesity and hypertension. Diabetes Metab Resand Rev. 2015;31:368-75.

  14. Mora García G, Salguedo Madrid G, Ruiz Díaz M, Ramos Clason E, Alario Bello A, Fortich A, et al. Concordancia entre cinco definiciones de síndrome metabólico. Cartagena, Colombia. Rev. Esp. Salud Pública. 2012;86:301-11.

  15. Fernández R, Arranz MC, Ortega JA, Hernández J. Resistencia a la insulina y cambios metabólicos en adultos obesos. Rev Cubana Endocrinol. 2011;22(2):78-90.

  16. Cabrera Rode E, Cálix Iglesias WD, Stusser Iglesias BI, Parlá Sardiñas J, Álvarez Álvarez A, Olano Justiniani R, et al. Relación de la resistencia a la insulina con el riesgo cardiovascular, según diferentes tablas y factores de riesgo cardiovascular en sujetos sobrepesos y obesos. Rev Cubana Endocrinol. 2013;24(2):136-52.

  17. Wei GS, Coady SA, Reis JP, Carnethon MR, Coresh J, D'Agostino RB Sr, et al. Duration and degree of weight gain and incident diabetes in younger versus middle-aged Black and White Adults: ARIC, CARDIA, and the Framingham Heart Study. Diabetes Care. 2015;38:2042-49.

  18. Galera R, García E, Vázquez MA. Prevalence of metabolic syndrome among adolescents in a city in the Mediterranean areas: comparison of two definitions. Nutr Hosp. 2015;32:627-33.

  19. Bhowmik B, Afsana F, Siddiquee T, Munir SB, Sheikh F. Comparison of the prevalence of metabolic syndrome and its association with diabetes population of Bangladesh using the modified National Cholesterol Education Program Expert Panel Adult Treatment Panel III and International Diabetes Federation definitions. J Diabetes Invest. 2015;6:380-8.

  20. Brady TM, Appel LJ, Holmes KW, Fivush B, Miller ER. Association between adiposity and left ventricular mass in children with hypertension. J Clin Hypertens (Greenwich). 2016;18(7):625-33.

  21. Scuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Mañas LR, et al. Metabolic syndrome across Europe: Different clusters of risk factors. Eur J Prev Cardiol. 2015;22:486-91.

  22. Simmons RK, Alberti KG, Gale EA, Colagiuri S, Tuomilehto J, Qiao Q, et al. The metabolic syndrome: Useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetología. 2010;53:600-5.

  23. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-2304.

  24. Kwasny C, Manuwald U, Kugler J, Rothe U. Systematic review of the epidemiology and natural history of the metabolic vascular syndrome and its coincidence with type 2 diabetes mellitus and cardiovascular diseases in different European countries. Horm Metab Res. 2018;50:201-8.

  25. Morejón-Giraldoni AF, Benet-Rodríguez M, Salas-Rodríguez V, Rivas-Álpizar E, Vásquez-Mendoza EM, Navarrete-Borrero AA. Fenotipo hipertrigliceridemia cintura abdominal alterada y su asociación con los factores de riesgo cardiovasculares. Rev Haban Cienc Med. 2018;17(6):949-64.

  26. Linares-Reyes E, Castillo-Minaya K, Ríos-Mino M, Huamán-Saavedra J. Estudio de correlación entre los diagnósticos de cintura hipertrigliceridémica y síndrome metabólico en adultos de Trujillo, Perú. Rev Perú Med Exp Salud Pública. 2014;31:254-60.

  27. Feliciano Pereira P, Rocha de Faria F, Rodríguez de Faria E, Miranda Hermsdorff HH, Gouveia Peluzio MC, Castro Franceschini SC, et al. Anthropometric indices to identify metabolic syndrome and hypertriglyceridemic waist phenotype: a comparison between the three stages of adolescence. Rev Paul Pediatr. 2015;33(2):194-203.

  28. Ren Y, Liu Y, Sun X, Deng K, Wang C, Li L, et al. Hypertriglyceridemia-waist and risk of developing type 2 diabetes: The rural Chinese cohort study. Sci Rep. 2017[acceso: 28/03/2020];7(1):9072. Disponible en: https://www.nature.com/articles/s41598-017-09136-x.pdf

  29. Ruíz-Fernández N, Rangel A, Rodríguez C, Rodríguez L, Rodríguez V. Circunferencia hipertrigliceridémica y perfil de riesgo cardio-metabólico en adolescentes normopeso y con exceso de peso. Rev. Fac. Med. 2015;63(2):181-91.

  30. Poirier J, Kubow S, Noël M, Dupont C, Egeland GM. The hypertriglyceridemic-waist phenotype is associated with the Framingham risk score and subclinical atherosclerosis in Canadian Cree. Nutr Metab Cardiovasc Dis. 2015;25(11):1050-5.

  31. Cabrera-Rode E, Borja Coronel AC, Montes de Oca Somoano R, Rodríguez Acosta J, Cubas-Dueñas I, Arnold Domínguez Y, et al. Utilidad del fenotipo hipertensión-obesidad abdominal para identificar personas con síndrome metabólico. Rev ALAD. 2020[acceso: 21/08/2020];10(4). Disponible en: https://www.revistaalad.com/frame_esp.php?id=445

  32. Zugasti A, Moreno B. Obesidad, factor de riesgo cardiovascular. Rev. Esp. Obes. 2005;3(2):89-94.

  33. Dueñas Herrera A, Armas Rojas N, Prohias Martinez J. Determinación del Riesgo Cardiovascular Global. Importancia de su implementación sistemática en el Sistema Nacional de Salud. Rev. Cubana. Cardiol. Cir. Cardiovasc. 2017[acceso: 21/08/2020];23(2). Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/689

  34. Álvarez Cosmea A. Las tablas de riesgo cardiovascular: una revisión crítica. Medifarm. 2001;11(3):35-49.

  35. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet. 2008;371:923-31.

  36. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2001;20(2):12. https://doi.org/10.1007/s11906-018-0812-z

  37. Ranasinghe P, Mathangasinghe Y, Jayawardena R, Hills AP, Misra A. Prevalence and trends of metabolic syndrome among adults in the Asian-pacific region: a systematic review. BMC Public Health. 2001[acceso: 281/03/2020]7;17(1):101. Disponible en: https://bmcpublichealth.biomedcentral.com/track/pdf/10.1186/s12889-019-6711-7

  38. Cabrera-Rode E, Orlandi N, Padrón Y, Arranz C, Olano R, Machado M, et al. Effect of Diamel in patients with metabolic syndrome: a randomised, double-blinded placebo-controlled study. J Diabetes. 2013;5(2):180-91.

  39. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5.

  40. Cabrera-Rode E, Stusser B, Cálix W, Orlandi N, Rodriguez J, Cuba-Dueñas I, et al. Concordancia diagnóstica entre siete definiciones de síndrome metabólico en adultos con sobrepeso y obesidad. Rev Perú Med Exp Salud Pública. 2017;34(1):19-27.

  41. Díaz O, Hernández J, Domínguez E, Martínez I, Bosch Y, del Busto A, et al. Valor de corte de la circunferencia de la cintura como predictor de disglucemia. Rev Cub Endocrinol. 2017;28(1):1-15.

  42. Whelton PK, Carey RM, Aronow WS, Casey Jr DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.J Am Coll Cardiol. 2018;71:127-248.

  43. Morejón-Giraldoni A, Rivas-Alpízar E, Salas-García V, Benet-Rodríguez M. Prevalencia del fenotipo hipertrigliceridemia cintura abdominal alterada: resultados de la segunda medición de la iniciativa CARMEN. Revista Finlay. 2014[acceso: 28/03/2020];4(4): Disponible en: http://www.revfinlay.sld.cu/index.php/finlay/article/view/321

  44. Nita C, Hancu N, Rusu A, Bala C. Hypertensive waist: First step of the screening for metabolic syndrome. Metab Syndr Relat Disord. 2009;7:105-10.

  45. Quing L, Wen R, Chan L, Xiaoya Z, Xin X. Sensitivity of various body indices and visceral adiposity index in predicting metabolic syndrome among Chinese patients with adult growth hormone deficiency J Endocrinol Invest. 2017;40:653-61.

  46. Mori Vara. Prevalencia de la obesidad y el sobrepeso de una población universitaria de la Comunidad de Madrid (2017), Pilar Nutr. clin. diet. hosp. 2018;38(1):102-13.

  47. Seon JJ, Lim YJ, Lee HW, Yoon JM, Kim SJ, Choi S, et al. Cardiovascular health status between standard and nonstandard workers in Korea. PLoS ONE. 2017;12(6):e0178395. https://doi.org/10.1371/journal.pone.0178395

  48. Kelishadi R, Jamshidi F, Qorbanib M, Motlaghd ME, Heshmat R, Ardalana G, et al. Association of hypertriglyceridemic-waist phenotype with liver enzymes and cardiometabolic risk factors in adolescents: the CASPIAN-III study. J Pediatr (Rio J). 2016;92(5):512-20.

  49. Kjeldsen SE. Hypertension and cardiovascular risk: General aspects. Pharmacol Res. 2018;129:95-99.

  50. Manios Y, Karatzi K, Protogerou AD, Moschonis G, Tsirimiagou C, et al. Prevalence of childhood hypertension and hypertension phenotypes by weight status and waist circumference: The Healthy Growth Study. European Journal of Nutrition. 2018;57:1147-55.

  51. Ribas de Farias Costa P, Marlúcia Oliveira Assis A, De Magalhães Cunha C, Miranda Pereira E, Dos Santos de Jesus G, Machado da Silva LE, et al. Hypertriglyceridemic Waist Phenotype and Changes in the Fasting Glycemia and Blood Pressure in Children and Adolescents Over One-Year Follow-Up Period. Arq Bras Cardiol. 2017;109(1):47-53.

  52. Javier Sangrós F, Torrecilla J, Giraldéz-García C, Carrillo L, Mancera J, Mur T, et al. Asociación de obesidad general y abdominal con hipertensión, dislipidemia y presencia de prediabetes en el estudio PREDAPS. Rev Esp Cardiol. 2018;71(3):170-77.

  53. Espinosa De Ycaza AE, Donegan D, Jensen MD. Long-term metabolic risk for the metabolically healthy overweight/obese phenotype Inter J Obes (Lond). 2018;42(3):302-9.

  54. Chandra A, Neeland IJ, Berry JD, Ayers CR, Rohatgi A, Das SR, et al. The relationship of body mass and fat distribution with incident hypertension: Observations from the Dallas Heart Study. J Am Coll of Cardiol. 2014;64(10):997-1002.




2020     |     www.medigraphic.com